International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 517-518 , May 2010

Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness

  • Burke A. Cunha

      Affiliations

    • Infectious Disease Division, Winthrop-University Hospital, Mineola, NY, USA
    • State University of New York School of Medicine Stony Brook, NY, USA
    • Corresponding Author InformationPresent address: Infectious Disease Division, Winthrop-University Hospital, Mineola, NY 11501, USA. Tel.: +1 516 663 2505; fax: +1 516 663 2753.

References 

  1. Cunha BA. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect. 2005;11(Suppl. 4):33–42
  2. Cunha BA. The significance of antibiotic false sensitivity testing with in vitro testing. J Chemother. 1997;9:25–35
  3. Kucers A, Crowe SM, Grayson ML, Hoy JF. The use of antibiotics. 5th ed.. Oxford, UK: Butterworth Heinemann; 1997;p. 719–63
  4. Cunha BA. Oral antibiotic treatment of MRSA infections. J Hosp Infect. 2005;60:88–90[erratum in: J Hosp Infect 2006;62:130]
  5. Cunha BA. Antibiotic essentials. 9th ed.. Sudbury, MA: Jones & Bartlett; 2010;
  6. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355–366
  7. Schwartz BS, Graber CJ, Diep BA, Basuino L, Perdreau-Remington F, Chambers HF. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin Infect Dis. 2009;48:1483–1484

PII: S0924-8579(10)00062-2

doi: 10.1016/j.ijantimicag.2010.01.017

International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 517-518 , May 2010

Article Tools